Freeze-thaw is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-24. Numbers and descriptions here follow the published literature rather than marketing material.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Of 27 beef burger products tested, 37% were positive for horse DNA, and 85% were positive for pig DNA. Of 31 beef meal products tested, 21 were positive for pig DNA, but all were negative for horse DNA. Nineteen salami products were tested, but were negative for all foreign DNA. Of the 37% of beef products tested positive for horse DNA, Tesco's Everyday Value Beef Burgers tested at 29.1%. All other reported brands had less than 0.3% horse DNA. These products originated from Liffey Meats and Silvercrest Foods in Ireland, and from the Dalepak Hambleton food processing plant in the United Kingdom. Trace amounts of horse DNA were also found in raw ingredients imported from Spain and the Netherlands. Laboratory DNA investigations were requested by the authorities into possible donkey meat adulteration of minced meat products labelled as 100% beef. British company Primerdesign provided many of the tests to laboratories and companies wishing to test for contamination.
=== Neo === Counter-Strike Neo (stylized NEO) is a Japanese arcade adaptation of Counter-Strike published by Namco for Linux-based machines. The game is set in a futuristic version of Counter-Strike, with characters featuring anime-like designs. A selection of single-player missions, mini-games, and seasonal events were added to prolong the players' interest on the game.
Lilly's biosynthetic recombinant insulin, branded as Humulin, was introduced in 1983. In 1985, Axel Ullrich sequenced the human insulin receptor, further enhancing the understanding of insulin's biological mechanisms. By 1988, Novo Nordisk produced synthetic recombinant human insulin, which further improved insulin availability and consistency.
=== Aftermath of the conflict === According to the cable sent from Astana, Chinese Ambassador Cheng Guoping told American Ambassador to Kazakhstan in June 2009 that he expected Russia to use military force to depose Saakashvili. US Ambassador to Russia John Beyrle advised the US government in June 2009 against military cooperation with Georgia since it would harm "re-start relations with Russia", while US Ambassador to Georgia supported maintaining ties with Georgia. The cables reported that Assistant Secretary of State Philip H. Gordon was told by the French diplomatic adviser Jean-David Levitte in September 2009 that "it may take a generation before the Russian public will be able to accept their loss of influence, from Poland and the Baltics to Ukraine and Georgia. Unfortunately, the Russian tendency is to view « good neighbors » as totally submissive subordinates." Gordon said that "the U.S. pursues a policy to support Georgia in the face of Russian pressure without encouraging President Saakashvili to act in ways that are unhelpful." In September 2009, United States Assistant Secretary of Defense Alexander Vershbow told Russian Deputy Foreign Minister Grigory Karasin that the US non-lethal military aid to Georgia was "a matter of principle" and the US did "not accept any arms embargo".
Good agricultural practice (GAP), for farming and ranching Good clinical practice (GCP), for hospitals and clinicians conducting clinical studies on new drugs in humans Good distribution practice (GDP) deals with the guidelines for the proper distribution of medicinal products for human use. Good laboratory practice (GLP), for laboratories conducting non-clinical studies (toxicology and pharmacology studies in animals) Good pharmacovigilance practice (GVP), for the safety of produced drugs Good regulatory practice (GRP), for the management of regulatory commitments, procedures and documentation Collectively, these and other good-practice requirements are referred to as "GxP" requirements, all of which follow similar philosophies. Other examples include good guidance practice and good tissue practice.
Sources: en.wikipedia.org
=== Names === Esketamine is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while esketamine hydrochloride is its BANMTooltip British Approved Name, Modified. It is also known as S(+)-ketamine, (S)-ketamine, or (–)-ketamine ((-)[+] ketamine), as well as by its developmental code name JNJ-54135419. Esketamine is sold under the brand name Spravato for use as an antidepressant and the brand names Eskesia, Ketanest, Ketanest S, Ketanest-S, Keta-S for use as an anesthetic (veterinary), among others.
Relative to 150 mg/day bicalutamide, levels of (R)-bicalutamide are about 15% higher at a dosage of 200 mg/day and about 50% higher at a dosage of 300 mg/day. In contrast to (R)-bicalutamide, the inactive enantiomer (S)-bicalutamide is much more rapidly absorbed (as well as cleared from circulation). Steady-state concentrations of the drug are reached after 4 to 12 weeks of administration independently of dosage, with an approximate 10- to 20-fold progressive accumulation of circulating levels of (R)-bicalutamide. The relatively long time to reach steady-state is a product of the long elimination half-life of bicalutamide. With single 50 mg and 150 mg doses of bicalutamide, mean peak concentrations (Cmax) of (R)-bicalutamide are 0.77 μg/mL (1.8 μmol/L) (at 31 hours) and 1.4 μg/mL (3.3 μmol/L) (at 39 hours), respectively. At steady-state, mean circulating concentrations (Css) of (R)-bicalutamide with 50 mg/day and 150 mg/day bicalutamide are 8.85 μg/mL (20.6 μmol/L) and 21.6 μg/mL (50.2 μmol/L), respectively. In another 150 mg/day bicalutamide study, mean circulating concentrations of (R)-bicalutamide were 19.4 μg/mL (45.1 μmol/L) and 28.5 μg/mL (66.3 μmol/L) on days 28 and 84 (weeks 4 and 12) of treatment, respectively. There is wide interindividual variability, up to 15.7-fold, in steady-state (R)-bicalutamide levels with bicalutamide therapy. This is the case for all dosage levels of bicalutamide, and ranges in (R)-bicalutamide levels for different dosages show significant overlap.
=== Workforce and operational practices === In 2022, Eucalyptus had to cut 20% of its staff from across their brands after an investment firm pulled out of its decision to loan the company money. The investment firm was not named however the layoffs affected 50 to 60 people across multiple brands of the company. Comparable overseas start-ups, such as Ro (company) and Hims & Hers Health have faced similar struggles. In 2026, four current and former medical assistants from the Philippines spoke anonymously against Eucalyptus and their "impossible" benchmarks that were raised in 2025. It is alleged that Eucalyptus raised the number of queries that each assistant should process to more than 65 a day, with some employees assigned up to 80 new tickets. Failing to meet these metrics leads to escalation from management with fear of termination. The pressure aligns with Eucalyptus' growth however has led to increased employee turnover and dependence on AI.
=== In popular culture === The movie A Civil Action, starring John Travolta, was based on the Grace groundwater contamination lawsuits in Woburn, Massachusetts. The PBS television show P.O.V., which highlights independent films, in August 2007 premiered the movie Libby, Montana which documents the thousands of people in Libby, Montana, that have been exposed to and are suffering the effects of asbestos exposure. The show also discusses the criminal indictments of many Grace executives for covering up asbestos related illnesses and deaths. PBS also aired Dust to Dust, a documentary produced by Michael Brown Productions, Inc. in 2002. Dust to Dust reports on the more than 200 people who have died from asbestos exposure in Libby, Montana. The film focuses on the plights of several of these individuals and the damage done over almost 30 years while the mine was operated by W. R. Grace. NPR aired a piece on All Things Considered discussing the criminal charges against W. R. Grace. A U.S. attorney general alleges that the company and managers of the mine in Libby, Montana, knew about the dangers of the asbestos they were dumping into the air for over 20 years. On February 19, 2008, the NPR-produced radio show Here and Now broadcast a story about the film Libby, Montana, which details the asbestos contamination in the town of that name. On April 22, 2009, the television and radio program Democracy Now! broadcast two segments on the trial of W. R. Grace and some of its employees related to the asbestos contamination in Libby, Montana.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.